NCT01636271View on ClinicalTrials.gov

SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)

CompletedOBSERVATIONAL
Enrollment

28,855

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Coronary Heart Disease
Interventions
DRUG

darapladib

darapladib enteric coated tablets 160 mg

DRUG

placebo

placebo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01636271 - SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033) | Biotech Hunter | Biotech Hunter